Cell MedX Corp. (CMXC)
USD 0.43
(0.0%)
USD 0.43
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 244.05 Thousand USD | -70.08% |
| 2023 | 902.72 Thousand USD | 52.38% |
| 2022 | 592.4 Thousand USD | 83.45% |
| 2021 | 322.91 Thousand USD | -29.39% |
| 2020 | 457.34 Thousand USD | 0.61% |
| 2019 | 454.58 Thousand USD | 316.06% |
| 2018 | 109.25 Thousand USD | -76.94% |
| 2017 | 473.8 Thousand USD | -48.73% |
| 2016 | 924.15 Thousand USD | 239.09% |
| 2015 | 272.54 Thousand USD | 1377.51% |
| 2014 | 18.44 Thousand USD | 887.47% |
| 2013 | 1868.00 USD | 107.91% |
| 2012 | -23.61 Thousand USD | -138811.76% |
| 2011 | -17.00 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 998.35 Thousand USD | 10.59% |
| 2024 FY | 244.05 Thousand USD | -72.97% |
| 2024 Q4 | 244.05 Thousand USD | 0.71% |
| 2024 Q3 | 242.32 Thousand USD | -76.02% |
| 2024 Q2 | 1.01 Million USD | 1.22% |
| 2023 Q2 | 747.45 Thousand USD | 11.11% |
| 2023 Q3 | 861.39 Thousand USD | 15.24% |
| 2023 Q1 | 672.72 Thousand USD | 13.56% |
| 2023 FY | 902.72 Thousand USD | 52.38% |
| 2023 Q4 | 902.72 Thousand USD | 4.8% |
| 2022 Q3 | 530.43 Thousand USD | 21.84% |
| 2022 Q1 | 313.93 Thousand USD | -2.78% |
| 2022 Q2 | 435.33 Thousand USD | 38.67% |
| 2022 FY | 592.4 Thousand USD | 83.45% |
| 2022 Q4 | 592.4 Thousand USD | 11.68% |
| 2021 Q3 | 731.33 Thousand USD | 17.13% |
| 2021 FY | 322.91 Thousand USD | -29.39% |
| 2021 Q4 | 322.91 Thousand USD | -55.85% |
| 2021 Q1 | 471.42 Thousand USD | 3.08% |
| 2021 Q2 | 624.38 Thousand USD | 32.45% |
| 2020 Q2 | 88.83 Thousand USD | 146.68% |
| 2020 FY | 457.34 Thousand USD | 0.61% |
| 2020 Q1 | -190.29 Thousand USD | -141.86% |
| 2020 Q3 | 309.83 Thousand USD | 248.78% |
| 2020 Q4 | 457.34 Thousand USD | 47.61% |
| 2019 Q4 | 454.58 Thousand USD | 31.72% |
| 2019 Q1 | 157.2 Thousand USD | 43.88% |
| 2019 Q2 | 169.99 Thousand USD | 8.13% |
| 2019 FY | 454.58 Thousand USD | 316.06% |
| 2019 Q3 | 345.1 Thousand USD | 103.01% |
| 2018 Q3 | 76.6 Thousand USD | 894.94% |
| 2018 Q1 | 248.33 Thousand USD | -47.59% |
| 2018 FY | 109.25 Thousand USD | -76.94% |
| 2018 Q4 | 109.25 Thousand USD | 42.62% |
| 2018 Q2 | -9637.00 USD | -103.88% |
| 2017 FY | 473.8 Thousand USD | -48.73% |
| 2017 Q1 | 1.08 Million USD | 17.36% |
| 2017 Q2 | 12.14 Thousand USD | -98.88% |
| 2017 Q3 | 273.72 Thousand USD | 2153.28% |
| 2017 Q4 | 473.8 Thousand USD | 73.09% |
| 2016 Q1 | 392.32 Thousand USD | 43.95% |
| 2016 FY | 924.15 Thousand USD | 239.09% |
| 2016 Q4 | 924.15 Thousand USD | 40.24% |
| 2016 Q3 | 658.99 Thousand USD | 37.8% |
| 2016 Q2 | 478.21 Thousand USD | 21.89% |
| 2015 Q2 | 125.03 Thousand USD | 2316.99% |
| 2015 Q1 | 5173.00 USD | -71.96% |
| 2015 Q4 | 272.54 Thousand USD | 61.05% |
| 2015 FY | 272.54 Thousand USD | 1377.51% |
| 2015 Q3 | 169.23 Thousand USD | 35.35% |
| 2014 Q4 | 18.44 Thousand USD | 23.42% |
| 2014 Q3 | 14.94 Thousand USD | 41.32% |
| 2014 Q2 | 10.57 Thousand USD | 40.36% |
| 2014 Q1 | 7535.00 USD | 303.37% |
| 2014 FY | 18.44 Thousand USD | 887.47% |
| 2013 Q4 | 1868.00 USD | 114.85% |
| 2013 FY | 1868.00 USD | 107.91% |
| 2013 Q2 | -18.91 Thousand USD | 19.92% |
| 2013 Q1 | -23.61 Thousand USD | 0.0% |
| 2013 Q3 | -12.57 Thousand USD | 33.48% |
| 2012 Q4 | -23.61 Thousand USD | 21.33% |
| 2012 Q3 | -30.01 Thousand USD | -176470.59% |
| 2012 FY | -23.61 Thousand USD | -138811.76% |
| 2012 Q1 | -17.00 USD | 0.0% |
| 2012 Q2 | -17.00 USD | 0.0% |
| 2011 Q4 | -17.00 USD | 0.0% |
| 2011 FY | -17.00 USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| RetinalGenix Technologies Inc. | 506.53 Thousand USD | 51.819% |